Localized Cutaneous Adverse Event Induced by Anastrozole as Adjuvant Treatment for Breast Cancer: A Case Report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Localized Cutaneous Adverse Event Induced by Anastrozole as Adjuvant Treatment for Breast Cancer: A Case Report ; volume:11 ; number:1 ; year:2019 ; pages:57-63
Case reports in dermatology ; 11, Heft 1 (2019), 57-63
- Urheber
-
Tanaka, Aya
Yamashita, Chigusa
Hinogami, Haruna
Shirai, Hirohiko
Yamamura, Jun
Ito, Ryota
- DOI
-
10.1159/000497469
- URN
-
urn:nbn:de:101:1-2019051601192033145245
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tanaka, Aya
- Yamashita, Chigusa
- Hinogami, Haruna
- Shirai, Hirohiko
- Yamamura, Jun
- Ito, Ryota
Ähnliche Objekte (12)
Cutaneous adverse events associated with interferon-β treatment of multiple sclerosis
Cutaneous adverse events associated with long-term immunomodulating therapy in multiple sclerosis
Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
CACA guidelines for holistic integrative management of anticancer treatment - induced cutaneous adverse events
Adverse cutaneous drug eruptions : 34 tables
Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases
Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany
Concomitant visceral and localized cutaneous leishmaniasis in two Moroccan infants
Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events
Multiple drug hypersensitivity associated with severe cutaneous adverse reaction
Management of immune-related adverse events in anti-PD-1-treated patients with advanced cutaneous squamous cell carcinoma
Cutaneous adverse events associated with interferon-β treatment of multiple sclerosis
Cutaneous adverse events associated with long-term immunomodulating therapy in multiple sclerosis
Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
CACA guidelines for holistic integrative management of anticancer treatment - induced cutaneous adverse events
Adverse cutaneous drug eruptions : 34 tables
Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases
Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany
Concomitant visceral and localized cutaneous leishmaniasis in two Moroccan infants
Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events
Multiple drug hypersensitivity associated with severe cutaneous adverse reaction
Management of immune-related adverse events in anti-PD-1-treated patients with advanced cutaneous squamous cell carcinoma
Cutaneous adverse events associated with interferon-β treatment of multiple sclerosis
Cutaneous adverse events associated with long-term immunomodulating therapy in multiple sclerosis
Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
CACA guidelines for holistic integrative management of anticancer treatment - induced cutaneous adverse events
Adverse cutaneous drug eruptions : 34 tables
Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases
Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany
Concomitant visceral and localized cutaneous leishmaniasis in two Moroccan infants
Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events
Multiple drug hypersensitivity associated with severe cutaneous adverse reaction